<?xml version='1.0' encoding='utf-8'?>
<document id="29102550"><sentence text="A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4."><entity charOffset="95-108" id="DDI-PubMed.29102550.s1.e0" text="Buprenorphine" /></sentence><sentence text="CAM2038, FluidCrystal injection depot, is an extended release formulation of buprenorphine given subcutaneously every 1 week (Q1W) or every 4 weeks (Q4W)"><entity charOffset="77-90" id="DDI-PubMed.29102550.s2.e0" text="buprenorphine" /></sentence><sentence text=" The purpose of this research was to predict the magnitude of drug-drug interaction (DDI) after coadministration of a strong CYP3A4 inducer or inhibitor using physiologically based pharmacokinetic (PBPK) modeling" /><sentence text=" A PBPK model was developed for CAM2038 based on the previously published buprenorphine PBPK model after intravenous and sublingual administration and the PK profiles after subcutaneous administration of CAM2038 from 2 phase I clinical trials"><entity charOffset="74-87" id="DDI-PubMed.29102550.s4.e0" text="buprenorphine" /></sentence><sentence text=" The strong CYP3A4 inhibitor ketoconazole was predicted to increase the buprenorphine exposure by 35% for the Q1W formulation and 34% for Q4W formulation, respectively"><entity charOffset="29-41" id="DDI-PubMed.29102550.s5.e0" text="ketoconazole" /><entity charOffset="72-85" id="DDI-PubMed.29102550.s5.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.29102550.s5.e0" e2="DDI-PubMed.29102550.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29102550.s5.e0" e2="DDI-PubMed.29102550.s5.e1" /></sentence><sentence text=" Also, the strong CYP3A4 inducer rifampin was predicted to decrease the buprenorphine exposure by 26% for both the Q1W and Q4W formulations"><entity charOffset="33-41" id="DDI-PubMed.29102550.s6.e0" text="rifampin" /><entity charOffset="72-85" id="DDI-PubMed.29102550.s6.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.29102550.s6.e0" e2="DDI-PubMed.29102550.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29102550.s6.e0" e2="DDI-PubMed.29102550.s6.e1" /></sentence><sentence text=" The results provided insight into the potential DDI effect for CAM2038 and suggested a lack of clinically meaningful DDI when CAM2038 is coadministered with CYP3A4 inhibitor or inducer" /><sentence text=" Therefore, no dose adjustment is required when CAM2038 is coadministered with CYP3A4 perpetrators" /><sentence text="" /></document>